2016 Fiscal Year Final Research Report
Development of a halogenated derivative of aromatic amino acids for the targeted alpha-radionuclide therapy with high tumor specificity and low renal background.
Project/Area Number |
16H06942
|
Research Category |
Grant-in-Aid for Research Activity Start-up
|
Allocation Type | Single-year Grants |
Research Field |
General pharmacology
|
Research Institution | Osaka University |
Principal Investigator |
Wei Ling 大阪大学, 医学系研究科, 特任助教(常勤) (80783638)
|
Project Period (FY) |
2016-08-26 – 2017-03-31
|
Keywords | 癌 / α線内用療法 / トランスポーター / 構造活性相関 / ハロゲン化芳香族アミノ酸誘導体 |
Outline of Final Research Achievements |
Targeted α-radionuclide therapy (TAT) is an upcoming powerful method for cancer treatment. One of halogens, 211At, has been attracting increasing attention as a novel α-particle emitting-radionuclide. A halogenated derivative of aromatic amino acid, FAMT (L-[3-18F]-α-methyltyrosine), developed as a PET tracer for tumor imaging exhibits an excellent cancer specificity. Therefore, substitution of 18F of FAMT with 211At would be a promising approach to develop a novel 211At-delivery agent for TAT. However, FAMT shows a significant background accumulation in kidney, due to the interaction with organic ion transporters in the renal proximal tubule. In this study, we used FAMT-related aromatic amino acid derivatives to reveal the molecular structures involved in the recognition by the renal organic ion transporters. This study gives significant implications for the development of a novel compound for TAT with high tumor specificity and low renal background accumulation.
|
Free Research Field |
薬理学
|